Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bugger
C Bode

Hamostaseologie

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Hamostaseologie|November 20, 2014
The vulnerable myocardium. Diabetic cardiomyopathyH Bugger, C Bode
Hamostaseologie|March 29, 2018
The vulnerable myocardiumH Bugger, C Bode
Hamostaseologie|May 6, 2006
[Inhibition of plasmatic coagulation: what is new?]M Schwarz, C Bode
Hamostaseologie|February 19, 2008
[Anticoagulation in acute coronary syndrome. An update]M Moser, C Bode
Hamostaseologie|August 4, 2012
Are new antithrombotics the modern fountain of youth? Achievements and limitationsM Moser, C Bode
Hamostaseologie|July 13, 2012
Oral anticoagulation with edoxaban. Focus on current phase III clinical developmentI Ahrens, C Bode
Hamostaseologie|March 29, 2018
Oral anticoagulation with edoxabanI Ahrens, C Bode
Hamostaseologie|November 3, 2009
[The role of serotonin in haemostasis]D Duerschmied, C Bode
Hamostaseologie|July 11, 2012
Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?D Duerschmied, C Bode
Hamostaseologie|March 29, 2018
Vorapaxar expands antiplatelet optionsD Duerschmied, C Bode
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Hamostaseologie|November 20, 2014
The vulnerable myocardium. Diabetic cardiomyopathyH Bugger, C Bode
Hamostaseologie|March 29, 2018
The vulnerable myocardiumH Bugger, C Bode
Hamostaseologie|May 6, 2006
[Inhibition of plasmatic coagulation: what is new?]M Schwarz, C Bode
Hamostaseologie|February 19, 2008
[Anticoagulation in acute coronary syndrome. An update]M Moser, C Bode
Hamostaseologie|August 4, 2012
Are new antithrombotics the modern fountain of youth? Achievements and limitationsM Moser, C Bode
Hamostaseologie|July 13, 2012
Oral anticoagulation with edoxaban. Focus on current phase III clinical developmentI Ahrens, C Bode
Hamostaseologie|March 29, 2018
Oral anticoagulation with edoxabanI Ahrens, C Bode
Hamostaseologie|November 3, 2009
[The role of serotonin in haemostasis]D Duerschmied, C Bode
Hamostaseologie|July 11, 2012
Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?D Duerschmied, C Bode
Hamostaseologie|March 29, 2018
Vorapaxar expands antiplatelet optionsD Duerschmied, C Bode
Pageof 3